Abstract
Advera Health Analytics launched Evidex in 2016. The database provides information on drug safety and adverse events.
Highlights
The health care informatics company Advera Health Analytics launched Evidex in 2016
The clinical trials results are selected from ClinicalTrials.gov and other published research with “over 2,000 drugs covered in the database and over 800 clinical trials” [1]
Advera Health Analytics states that “2018 WILL BE the year that the pharmacovigilance industry embraces the generation of drug safety data, analytics, and software, what we call Pharmacovigliance 2.0” [2]
Summary
The database provides information on drug safety and adverse events. Evidex was designed from the ground up to fill this important data and analytics gap” [1] Users can search this resource for individual drugs or compare their differences in costs, outcomes, safety, efficacy, and more. According to Advera Health Analytics, its: proprietary clinical trials safety outcomes database, when linked with optimized post-approval spontaneous reporting data from the FDA Adverse Event Reporting System (FAERS) and Vigibase, claims data and social media provides pharmacovigilance professionals with software, data and analytics to track emerging safety issues through multiple data sets, validate signals seen in spontaneous reporting and engage across these various data sets in dynamic and proactive manner.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
